2016 Press Releases


Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
November 8, 2016
Xenon Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference
BURNABY, British Columbia, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Stifel 2016 Healthcare C... More >>
November 3, 2016
Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update
BURNABY, British Columbia, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended September 30, 2016 and provided a corporate update. Dr. Simon Pimstone, Xenon's President... More >>
October 27, 2016
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2016 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 third quarter financial and operating results after the close of U.S. financial markets on Thursday, Novem... More >>
September 27, 2016
Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors
BURNABY, British Columbia, Sept. 27, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dawn Svoronos has been appointed to its Board of Directors. Ms. Svoronos is a pharmaceutical industry executive whose experience ... More >>
September 13, 2016
Xenon Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Closing of $34.5 Million Public Offering
BURNABY, British Columbia, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that the underwriters of the previously announced public offering of its common shares have exercised in full their option to purchase... More >>
September 8, 2016
Xenon Pharmaceuticals Announces Pricing of $30 Million Public Offering of Common Shares
BURNABY, British Columbia, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the pricing of a $30 million underwritten public offering of its common shares pursuant to its existing shelf registration statement a... More >>
September 7, 2016
Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares
BURNABY, British Columbia, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common shares pursuant to its existing shelf registration statement and c... More >>
August 3, 2016
Xenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
BURNABY, British Columbia, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended June 30, 2016 and provided a corporate update. Dr. Simon Pimstone, Xenon's President and ... More >>
August 2, 2016
Xenon Pharmaceuticals to Present at the Canaccord Genuity 36th Annual Growth Conference
BURNABY, British Columbia, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Canaccord Genuity 36th A... More >>
July 25, 2016
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update
BURNABY, British Columbia, July 25, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 second quarter financial and operating results after the close of U.S. financial markets on Wednesday, Aug... More >>
June 8, 2016
Xenon Pharmaceuticals Presents Corporate Update and Highlights Its Proprietary Therapeutic Programs at the Jefferies 2016 Healthcare Conference
BURNABY, British Columbia, June 08, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present today at the Jefferies 2016 Healthcare Conference in New... More >>
June 2, 2016
Xenon Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
BURNABY, British Columbia, June 02, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Jefferies 2016 Healthcar... More >>
May 10, 2016
Xenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
BURNABY, British Columbia, May 10, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended March 31, 2016 and provided a corporate update. Dr. Simon Pimstone, Xenon's President and ... More >>
May 2, 2016
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results and Provide Corporate Update
BURNABY, British Columbia, May 02, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 first quarter financial and operating results after the close of U.S. financial markets on Tuesday, May 10,... More >>
April 4, 2016
Xenon Names Dr. Raymond J. Winquist as Head, Translational Research
BURNABY, British Columbia, April 04, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Raymond J. Winquist has been named as its Head, Translational Research, effective immediately. Reporting to the CEO, Dr. Winq... More >>
March 31, 2016
Xenon Pharmaceuticals to Provide Business and Milestone Update at Needham Healthcare Conference
BURNABY, British Columbia, March 31, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a business update, including progress toward mile... More >>
March 15, 2016
Xenon and Genentech Extend Collaborations Focused on Pain
BURNABY, British Columbia, March 15, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today provided an update on its two ongoing collaborations focused on identifying and developing novel pain targets and therapeutics with Genentech, a... More >>
March 8, 2016
Xenon Pharmaceuticals Reports 2015 Financial Results and Provides Corporate Update
Significant Progress in Proprietary Development Pipeline and Partnered Programs Initiated Phase 2 Trial of XEN801 in Moderate to Severe Acne; Results Anticipated in Fourth Quarter of 2016 BURNABY, British Columbia, March 08, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), ... More >>
March 1, 2016
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2015 Financial Results and Provide Corporate Update
BURNABY, British Columbia, March 01, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2015 financial and operating results after the close of U.S. financial markets on Tuesday, March 8, 2016. Xeno... More >>
February 10, 2016
Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne
BURNABY, British Columbia, Feb. 10, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it has commenced dosing patients in a Phase 2 clinical trial of XEN801, which is a stearoyl Co-A desaturase-1, or SCD1, inhibitor ... More >>
February 9, 2016
Xenon Names Dr. James R. Empfield Senior Vice President, Drug Discovery
BURNABY, British Columbia, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. James R. Empfield has been named as Senior Vice President, Drug Discovery, effective immediately. Reporting to Dr. Simon Pimst... More >>
January 11, 2016
Xenon Outlines Key Milestones for 2016
BURNABY, British Columbia, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated key corporate milestones for 2016. Dr. Simon Pimstone, Xenon’s President and Chief Executive Officer, stated: “Overal... More >>